Gan & Lee Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of recombinant insulin analogue raw materials and injections. Its products include recombinant insulin glargine injections, recombinant insulin lispro injections, protamine zinc recombinant insulin lispro mixed injections, injection pens and needles. The company was founded by Zhong Ru Gan, Yi Ru Gan and Xi Ru Gan on June 17, 1998 and is headquartered in Beijing, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company